Loading...
Market
Will Eli Lilly exercise an option for additional collaboration with Insitro by 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements or press releases from Eli Lilly or Insitro
Story
Insitro and Eli Lilly Announce AI Deal to Accelerate Genetic Medicine Development
Oct 9, 2024, 03:30 PM
Insitro has announced a collaboration with Eli Lilly and Company to accelerate the development of Insitro's genetic medicine using Lilly's proprietary GalNAc delivery technology and expertise in biologics design. The partnership aims to bring Insitro's discoveries to the clinic, with the first drug expected to enter clinical trials by 2026. Insitro retains full global rights to its discoveries, while Lilly is eligible to receive potential benefits from the collaboration. The collaboration also includes an AI deal between Insitro and Eli Lilly.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
No new partnerships • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
Yes • 50%
No • 50%
Yes, identified and announced • 33%
Yes, identified but not announced • 33%
No, not identified • 33%